WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012044537) SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/044537    International Application No.:    PCT/US2011/052984
Publication Date: 05.04.2012 International Filing Date: 23.09.2011
IPC:
C07D 401/04 (2006.01), C07D 401/14 (2006.01), C07D 403/04 (2006.01), C07D 417/14 (2006.01), C07D 417/04 (2006.01), A61K 31/4184 (2006.01), A61K 31/4439 (2006.01), A61K 31/506 (2006.01), A61P 35/00 (2006.01), A61K 31/4725 (2006.01), A61K 31/437 (2006.01)
Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road Princeton, New Jersey 08543-4000 (US) (For All Designated States Except US).
HUANG, Audris [US/US]; (US) (For US Only)
Inventors: HUANG, Audris; (US)
Agent: GREENBLATT, Gary, D.; Bristol-Myers Squibb Company P.O. Box 4000 Princeton, New Jersey 08543-4000 (US)
Priority Data:
61/388,837 01.10.2010 US
Title (EN) SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS
(FR) COMPOSÉS SUBSTITUÉS DE BENZIMIDAZOLE ET D'IMIDAZOPYRIDINE UTILES COMME MODULATEURS DE CYP17
Abstract: front page image
(EN)Disclosed are heteroaryl compounds of Formula (I), (I), or pharmaceutically acceptable salts thereof, wherein Z is CH or N; W is CR3 or N; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
(FR)L'invention divulgue des composés hétéroaryle de Formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci, Z représentant CH ou N; W représentant CR3 ou N; et R1, R2 et R3 étant définis dans le descriptif. L'invention divulgue également des procédés d'utilisation de tels composés dans le traitement d'au moins une affection associée au CYP17, telle que, par exemple, le cancer, et des compositions pharmaceutiques comprenant de tels composés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)